MET and osteosarcoma: These suggested that MET may co-cause disease progression with VEGFR2 in osteosarcoma.To verify whether MET is a factor contributing to Anlotinib resistance in osteosarcomacells, this study selected four osteosarcoma cell lines: U2OS, DuNN, SaOS-2, and HOS.